Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
$42.86
-$0.61(-1.22%)
At close: 4:00 PM EST
$42.86
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$24.10 - $60.34
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.46M
Market Cap
$4.07B
Enterprise Value$2.88B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$49.14M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding94,891,840
10 Day Avg. Volume1,872,328
30 Day Avg. Volume1,457,484
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)3975.39
P/FCF Ratio-17.97
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.88K
Enterprise Value/Gross Profit-32.39
Enterprise Value/Ebitda-6.24
Forecast
1Y Price Target
$80.00Price Target Upside86.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.99
Revenue Forecast (FY)$5.06M
Bulls Say, Bears Say
Bulls Say
Financial StrengthCrinetics ended Q3 with $1.1B on the balance sheet, which is guided to fund operations into 2029, positioning it well to advance its pipeline.
Market PositionCrinetics transitions to a commercial biotech, having developed Palsonify from discovery to FDA approval, marking a milestone achievement.
Product LaunchThe launch of Palsonify is anticipated with early adoption in the community setting being very encouraging, demonstrating Palsonify's differentiated profile.
Bears Say
Financial ForecastsIncreased 2025 expenses leading to updated 2025 outlook.
Investor SentimentShort Interest as a percentage of float is 14.3%, indicating a significant level of skepticism from investors.
Regulatory ChallengesThe IND delay in Grave's disease is unfortunate, but it is believed not to be due to target-related issues.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $60.34 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $4.07B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 101 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.244 by -$0.136.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.34.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 94,891,840 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.244. Following the earnings report the stock price went down -8.025%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.00 (86.65% Upside)
$80.00 (86.65% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.84%
12-Months-Change
Fundamentals
Return on Equity
-44.42%
Trailing 12-Months
Asset Growth
27.59%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch and positive market reception of PALSONIFY, which is expected to drive substantial growth. However, delays in the Graves' disease candidate and the SST3 agonist program were noted. Overall, the sentiment is positive given the successful launch and financial stability.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$80.00
▲(86.65% Upside)
Technical Analysis
Ligand Pharma
―
Ultragenyx Pharmaceutical
―
Apellis Pharmaceuticals
―
Akero Therapeutics
―
Kymera Therapeutics
―
Ownership Overview
1.93% Insiders
40.60% Mutual Funds
6.32% Other Institutional Investors
36.28% Public Companies and Individual Investors